# KEYNOTE-061 (NCT02370498)

> A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: previously treated advanced gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02370498
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
- Interventions: pembrolizumab; paclitaxel
- Enrollment: 592
- Primary outcome: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants
- Primary outcome: Overall Survival (OS) in PD-L1 Positive Participants

## Indexed commentary on KEYNOTE-061 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-061-nct02370498

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02370498", "email": "<work email>"}; the inbox owner confirms by the emailed link.